Summary proceedings from the bronchopulmonary dysplasia group

Pediatrics

Volumn 117, Issue 3, 2006, Pages

  Walsh, Michele C ^a   Szefler, Stanley ^b   Davis, Jonathan ^c   Allen, Marilee ^d   Van Marter, Linda ^e   Abman, Steve ^f   Blackmon, Lillian ^g   Jobe, Alan ^h  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

^c WINTHROP UNIVERSITY HOSPITAL   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e BOSTON CHILDREN S HOSPITAL   (United States)

^f Children's Hospital Colorado   (United States)

^g UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^h CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

Bronchopulmonary dysplasia; Therapeutics

Indexed keywords

DEXAMETHASONE; HYDROCORTISONE; CORTICOSTEROID;

CEREBRAL PALSY; CHRONIC LUNG DISEASE; CLINICAL TRIAL; COGNITIVE DEFECT; CONFERENCE PAPER; DISEASE CLASSIFICATION; GASTROINTESTINAL HEMORRHAGE; GROWTH DISORDER; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPERTROPHIC CARDIOMYOPATHY; INTESTINE PERFORATION; LOW BIRTH WEIGHT; LUNG DYSPLASIA; MORBIDITY; PREMATURITY; PRIORITY JOURNAL; CLASSIFICATION; CONTROLLED CLINICAL TRIAL; HOSPITALIZATION; METHODOLOGY; NEWBORN; RANDOMIZED CONTROLLED TRIAL; VERY LOW BIRTH WEIGHT;

ADRENAL CORTEX HORMONES; BRONCHOPULMONARY DYSPLASIA; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; INFANT, VERY LOW BIRTH WEIGHT; RANDOMIZED CONTROLLED TRIALS; SEVERITY OF ILLNESS INDEX;

EID: 33745553210     PISSN: 00314005     EISSN: 02105721     Source Type: Journal    
DOI: 10.1542/peds.2005-0620I     Document Type: Conference Paper

References (11)

1. Jobe AH, Bancalari E. Bronchopulmonary dysplasia. Am J Respir Crit Care Med. 2001;163:1723-1729
2. Walsh MC, Wilson-Costello D, Zadell A, Newman N, Fanaroff A. Safety, reliability, and validity of a physiologic definition of bronchopulmonary dysplasia. J Perinatol. 2003;23:451-456
3. Halliday HL, Ehrenkrantz RA, Doyle LW. Moderately early (7-14 days) postnatal corticosteroids for chronic lung disease in preterm infants. Cochrane Database Syst Rev. 2003;(1):CD001144
4. Massaro D, Massaro GD. Invited Review: pulmonary alveoli: formation, the "call for oxygen," and other regulators [published correction appears in Am J Physiol Lung Cell Mol Physiol. 2002;282:section L]. Am J Physiol Lung Cell Mol Physiol. 2002;282:L345-L358
5. Baud O, Foix-L'Helias L, Kaminski M, et al. Antenatal glucocorticoid treatment and cystic periventricular leukomalacia in very premature infants. N Engl J Med. 1999;341:1190-1196
6. Halliday HL, Ehrenkranz RA, Doyle LW. Early postnatal (<96 hours) corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database Syst. Rev. 1999;(1):CD00146
7. Stark AR, Carlo W, Tyson JE, et al. Adverse effects of early dexamethasone in extremely-low-birth-weight infants. National Institute of Child Health and Human Development Neonatal Research Network. N Engl J Med. 2001;344:95-101
8. Watterberg KL, Gerdes JS, Cole CH, et al. Prophylaxis of early adrenal insufficiency to prevent bronchopulmonary dysplasia: a multicenter trial. Pediatrics. 2004;114:1649-1657
9. American Academy of Pediatrics, Committee on Fetus and Newborn. Postnatal corticosteroids to treat or prevent chronic lung disease in preterm infants. Pediatrics. 2002;109:330-338
10. Durand M, Mendoza ME, Tantivit P, Kugelman A, McEvoy C. A randomized trial of moderately early low-dose dexamethasone therapy in very low birth weight infants: Dynamic pulmonary mechanics, oxygenation, and ventilation. Pediatrics. 2002;109:262-268
11. Ng GYT, de Silva O, Ohlsson A. Bronchodilators for the prevention and treatment of chronic lung disease in preterm infants. Cochrane Database Syst. Rev. 2003;(4):CD003214